Our results reveal that CCR9 controls the immune microenvironment of colorectal cancer differentially affecting both CD8+ T cells and Tregs, and that its absence results in an increase in the CD8+/Treg cell ratio, which promotes an enhanced anti-tumoral response. The gene discussed is CCR9; the disease is colorectal cancer.